<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835298</url>
  </required_header>
  <id_info>
    <org_study_id>PO20065*</org_study_id>
    <nct_id>NCT04835298</nct_id>
  </id_info>
  <brief_title>Breathlessness Assessment in Adult Patients With Myotonic Dystrophy Type 1</brief_title>
  <official_title>Characters) Dyspnea Assessment in Adult Patients With Myotonic Dystrophy Type 1: a Monocentric Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myotonic dystrophy type 1 (DM1) is one of the most common neuromuscular diseases in adults.&#xD;
      As respiratory dysfunction is the most common cause of death in patients with DM1, a&#xD;
      respiratory disease progression must be monitored combining symptom screening and respiratory&#xD;
      function testing, in order to identify the appropriate time to initiate non invasive&#xD;
      ventilation (NIV).&#xD;
&#xD;
      Dyspnea, one of the main respiratory symptoms, has been little studied in patients with DM1.&#xD;
&#xD;
      The main objective of this study is to provide the first multidimensional description of&#xD;
      dyspnea in patients with DM1.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  To compare respiratory symptoms according to the presence or not of criteria from&#xD;
           respiratory function testing to initiate NIV&#xD;
&#xD;
        -  To assess associations between dyspnea and respiratory function testing&#xD;
&#xD;
        -  To assess associations between dyspnea and number of Cytosine Thymine Guanine (CTG)&#xD;
           repeats&#xD;
&#xD;
        -  To assess associations between dyspnea and muscular strength&#xD;
&#xD;
        -  To assess associations between dyspnea and BMI&#xD;
&#xD;
        -  To assess associations between dyspnea and anxiety or depression&#xD;
&#xD;
        -  To assess associations between dyspnea and cognitive impairment&#xD;
&#xD;
        -  To assess associations between dyspnea and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2020</start_date>
  <completion_date type="Anticipated">July 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 3, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>Month 6</time_frame>
    <description>Borg scale at rest and after 6 minute walking test</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Myotonic Dystrophy Type 1 (DM1)</condition>
  <arm_group>
    <arm_group_label>Myotonic dystrophy type 1</arm_group_label>
    <description>adult patients with myotonic dystrophy type 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dyspnea</intervention_name>
    <description>questionnaires</description>
    <arm_group_label>Myotonic dystrophy type 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients with myotonic dystrophy type 1&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with myotonic dystrophy type 1 confirmed by genetic analysis&#xD;
&#xD;
          -  with an age older than 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  an ongoing or recent (i.e. within the last 4 weeks prior to study recruitment) medical&#xD;
             condition, including pulmonary exacerbations&#xD;
&#xD;
          -  patient already under non-invasive mechanical ventilation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claire Launois</last_name>
    <phone>3 26 78 83 70</phone>
    <phone_ext>0033</phone_ext>
    <email>claunois@chu-reims.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien JOLLY</last_name>
      <phone>326788472</phone>
      <phone_ext>33</phone_ext>
      <email>djolly@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

